196 related articles for article (PubMed ID: 28838454)
1. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
[TBL] [Abstract][Full Text] [Related]
2. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
[TBL] [Abstract][Full Text] [Related]
3. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
Takeishi K; Ikegami T; Yoshizumi T; Itoh S; Harimoto N; Harada N; Tsujita E; Kimura Y; Yamashita Y; Saeki K; Oki E; Shirabe K; Maehara Y
Transplant Proc; 2015 Apr; 47(3):794-5. PubMed ID: 25891734
[TBL] [Abstract][Full Text] [Related]
4. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
6. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
[TBL] [Abstract][Full Text] [Related]
7. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
Fabrizi F; D'Ambrosio R; Pallotti F; Berardinelli L; Messa P; Martin P; Aghemo A
Int J Artif Organs; 2014 Nov; 37(11):803-8. PubMed ID: 25362901
[TBL] [Abstract][Full Text] [Related]
8. Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis C: allo or autoimmune de novo hepatitis?
Merli M; Gentili F; Giusto M; Attili AF; Corradini SG; Mennini G; Rossi M; Corsi A; Bianco P
Dig Liver Dis; 2009 May; 41(5):345-9. PubMed ID: 19162574
[TBL] [Abstract][Full Text] [Related]
9. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.
Levitsky J; Fiel MI; Norvell JP; Wang E; Watt KD; Curry MP; Tewani S; McCashland TM; Hoteit MA; Shaked A; Saab S; Chi AC; Tien A; Schiano TD
Gastroenterology; 2012 May; 142(5):1132-1139.e1. PubMed ID: 22285805
[TBL] [Abstract][Full Text] [Related]
10. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
[TBL] [Abstract][Full Text] [Related]
11. Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
Manz M; Steuerwald M
Transpl Infect Dis; 2007 Mar; 9(1):60-1. PubMed ID: 17313476
[TBL] [Abstract][Full Text] [Related]
12. Acute hepatitis C infection in a renal transplant recipient: primacy of the liver or kidney?
Althaf MM; Abdelsalam MS; Rashwan M; Nadri Q
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24907214
[TBL] [Abstract][Full Text] [Related]
13. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of hepatitis C in patients on renal replacement therapy].
Tornai I; Mátyus J
Orv Hetil; 2007 Mar; 148(11):489-94. PubMed ID: 17350920
[TBL] [Abstract][Full Text] [Related]
16. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G
Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study.
ReViS-TC Study Group
Transplantation; 2011 Aug; 92(3):334-40. PubMed ID: 21659948
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
19. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
[TBL] [Abstract][Full Text] [Related]
20. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]